240 related articles for article (PubMed ID: 30877328)
1. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
Van Wilder P; Pirson M; Dupont A
Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
[TBL] [Abstract][Full Text] [Related]
2. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
3. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
Grimm SE; Strong M; Brennan A; Wailoo AJ
Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
[TBL] [Abstract][Full Text] [Related]
4. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
Maynou L; Cairns J
Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
[TBL] [Abstract][Full Text] [Related]
5. Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
[TBL] [Abstract][Full Text] [Related]
6. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
7. Drug Policy in the Czech Republic.
Skoupá J
Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
[TBL] [Abstract][Full Text] [Related]
8. Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome?
Van Wilder P; Dupont A
Value Health; 2008; 11(4):784-7. PubMed ID: 18179663
[TBL] [Abstract][Full Text] [Related]
9. The Development of the Romanian Scorecard HTA System.
Radu CP; Chiriac ND; Pravat AM
Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
[TBL] [Abstract][Full Text] [Related]
10. The impact of health technology assessment reports on decision making in Austria.
Zechmeister I; Schumacher I
Int J Technol Assess Health Care; 2012 Jan; 28(1):77-84. PubMed ID: 22233544
[TBL] [Abstract][Full Text] [Related]
11. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Blonda A; Barcina Lacosta T; Toumi M; Simoens S
Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
[No Abstract] [Full Text] [Related]
13. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
[TBL] [Abstract][Full Text] [Related]
14. Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers.
Enzing JJ; Himmler S; Knies S; Brouwer WBF
Value Health; 2022 Feb; 25(2):222-229. PubMed ID: 35094795
[TBL] [Abstract][Full Text] [Related]
15. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
16. The Australian Managed Entry Scheme: Are We Getting it Right?
Tuffaha HW; Scuffham PA
Pharmacoeconomics; 2018 May; 36(5):555-565. PubMed ID: 29478116
[TBL] [Abstract][Full Text] [Related]
17. Improving Access to High-Cost Technologies in the Asia Region.
Mundy L; Trowman R; Kearney B
Int J Technol Assess Health Care; 2019 Jan; 35(3):168-175. PubMed ID: 31122302
[TBL] [Abstract][Full Text] [Related]
18. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
[TBL] [Abstract][Full Text] [Related]
19. Novel approach to decision making for orphan drugs.
Decker B; Mlcoch T; Pustovalova A; Dolezal T
Int J Technol Assess Health Care; 2023 Feb; 39(1):e10. PubMed ID: 36748356
[TBL] [Abstract][Full Text] [Related]
20. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
Beletsi A; Koutrafouri V; Karampli E; Pavi E
Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]